Neutralizing monoclonal antibodies against highly pathogenic coronaviruses

Rong Xiang; Yang Wang; Lili Wang; Xiaoqian Deng; Shanshan Huo; Shibo Jiang; Fei Yu

doi:10.1016/j.coviro.2021.12.015

Neutralizing monoclonal antibodies against highly pathogenic coronaviruses

Curr Opin Virol. 2022 Apr:53:101199. doi: 10.1016/j.coviro.2021.12.015. Epub 2021 Dec 30.

Authors

Rong Xiang¹, Yang Wang¹, Lili Wang², Xiaoqian Deng¹, Shanshan Huo³, Shibo Jiang⁴, Fei Yu⁵

Affiliations

¹ College of Life Sciences, Hebei Agricultural University, Baoding, China.
² Research Center of Chinese Jujube, Hebei Agricultural University, Baoding, China.
³ College of Life Sciences, Hebei Agricultural University, Baoding, China; Hebei Key Laboratory of Analysis and Control of Zoonotic Pathogenic Microorganism, Baoding, China. Electronic address: shmhss@hebau.edu.cn.
⁴ Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China. Electronic address: shibojiang@fudan.edu.cn.
⁵ College of Life Sciences, Hebei Agricultural University, Baoding, China; Hebei Key Laboratory of Analysis and Control of Zoonotic Pathogenic Microorganism, Baoding, China. Electronic address: shmyf@hebau.edu.cn.

Abstract

The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) is a continuing worldwide threat to human health and social economy. Historically, SARS-CoV-2 follows SARS and MERS as the third coronavirus spreading across borders and continents, but far more dangerous with long-lasting symptomatic consequences. The current situation is strong evidence that coronaviruses will continue to be pathogens of consequence in the future, thus calling for the development of neutralizing antibody-based prophylactics and therapeutics for prevention and treatment of COVID-19 and other human coronavirus diseases. This review summarized the progresses of developing neutralizing monoclonal antibodies against infection of SARS-CoV-2, SARS-CoV, and MERS-CoV, and discussed their potential applications in prevention and treatment of COVID-19 and other human coronavirus diseases.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Neutralizing / therapeutic use
COVID-19*
Humans
Middle East Respiratory Syndrome Coronavirus*
SARS-CoV-2

Substances

Antibodies, Monoclonal
Antibodies, Neutralizing